| scholarly article | Q13442814 |
| P2093 | author name string | Dunn BM | |
| Goodenow MM | |||
| Sleasman JW | |||
| Farmerie WG | |||
| Barrie KA | |||
| Perez EE | |||
| Lamers SL | |||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | HIV | Q15787 |
| P304 | page(s) | 407-416 | |
| P577 | publication date | 1996-05-01 | |
| P1433 | published in | Virology | Q7934867 |
| P1476 | title | Natural variation in HIV-1 protease, Gag p7 and p6, and protease cleavage sites within gag/pol polyproteins: amino acid substitutions in the absence of protease inhibitors in mothers and children infected by human immunodeficiency virus type 1. | |
| P478 | volume | 219 |
| Q28469157 | A look inside HIV resistance through retroviral protease interaction maps |
| Q40763780 | Amino acid substitutions in Gag protein at non-cleavage sites are indispensable for the development of a high multitude of HIV-1 resistance against protease inhibitors |
| Q38934936 | C-Terminal HIV-1 Transframe p6* Tetrapeptide Blocks Enhanced Gag Cleavage Incurred by Leucine Zipper Replacement of a Deleted p6* Domain |
| Q81477463 | Clinical implications of discordant viral and immune outcomes following protease inhibitor containing antiretroviral therapy for HIV-infected children |
| Q28378131 | Comparison of inhibitor binding to feline and human immunodeficiency virus proteases: structure-based drug design and the resistance problem |
| Q47447715 | Covariation of amino acid positions in HIV-1 protease |
| Q27747736 | Crystallographic analysis of human immunodeficiency virus 1 protease with an analog of the conserved CA-p2 substrate -- interactions with frequently occurring glutamic acid residue at P2' position of substrates |
| Q42373203 | Detection of Replication Competent Lentivirus Using a qPCR Assay for VSV-G. |
| Q41040100 | Detection of human immunodeficiency virus type 1 antiretroviral resistance mutations by high-density DNA probe arrays |
| Q34012585 | Drug-associated changes in amino acid residues in Gag p2, p7(NC), and p6(Gag)/p6(Pol) in human immunodeficiency virus type 1 (HIV-1) display a dominant effect on replicative fitness and drug response |
| Q34295972 | Early selection in Gag by protective HLA alleles contributes to reduced HIV-1 replication capacity that may be largely compensated for in chronic infection |
| Q44103766 | Effect of sequence polymorphism and drug resistance on two HIV-1 Gag processing sites. |
| Q28372993 | Effect of substrate residues on the P2' preference of retroviral proteinases |
| Q34033572 | Effects of HIV-1 protease on cellular functions and their potential applications in antiretroviral therapy |
| Q42208913 | Effects of PRE and POST therapy drug-pressure selected mutations on HIV-1 protease conformational sampling. |
| Q39550164 | Effects of human immunodeficiency virus type 1 resistance to protease inhibitors on reverse transcriptase processing, activity, and drug sensitivity. |
| Q42549394 | Escape mutants of HIV-1 proteinase: enzymic efficiency and susceptibility to inhibition |
| Q33690287 | Estimate of the frequency of human immunodeficiency virus type 1 protease inhibitor resistance within unselected virus populations in vitro. |
| Q42931192 | Evolution of human immunodeficiency virus type 1 protease genotypes and phenotypes in vivo under selective pressure of the protease inhibitor ritonavir |
| Q28474984 | Gag mutations strongly contribute to HIV-1 resistance to protease inhibitors in highly drug-experienced patients besides compensating for fitness loss |
| Q36953990 | Genetic basis of hypersusceptibility to protease inhibitors and low replicative capacity of human immunodeficiency virus type 1 strains in primary infection |
| Q40787173 | Genetic determinants in HIV-1 Gag and Env V3 are related to viral response to combination antiretroviral therapy with a protease inhibitor |
| Q34050677 | HIV drug resistance and viral fitness. |
| Q33834118 | HIV protease: enzyme function and drug resistance |
| Q34050688 | HIV-1 protease: maturation, enzyme specificity, and drug resistance. |
| Q33804495 | Identification of a key target sequence to block human immunodeficiency virus type 1 replication within the gag-pol transframe domain |
| Q36633283 | Identification of active sites in amidase: evolutionary relationship between amide bond- and peptide bond-cleaving enzymes |
| Q37038403 | Identification of dual-tropic HIV-1 using evolved neural networks |
| Q28368369 | In vitro selection and characterization of human immunodeficiency virus type 1 variants with increased resistance to ABT-378, a novel protease inhibitor |
| Q39875739 | Influence of extended mutations of the HIV-1 transframe protein p6 on Nef-dependent viral replication and infectivity in vitro |
| Q47841916 | Killing HIV-infected cells by transduction with an HIV protease-activated caspase-3 protein |
| Q39579408 | Loss of viral fitness associated with multiple Gag and Gag-Pol processing defects in human immunodeficiency virus type 1 variants selected for resistance to protease inhibitors in vivo. |
| Q47252759 | Modeling the full length HIV-1 Gag polyprotein reveals the role of its p6 subunit in viral maturation and the effect of non-cleavage site mutations in protease drug resistance |
| Q36492224 | Modeling within-host HIV-1 dynamics and the evolution of drug resistance: trade-offs between viral enzyme function and drug susceptibility |
| Q34334101 | Molecular basis for substrate recognition and drug resistance from 1.1 to 1.6 angstroms resolution crystal structures of HIV-1 protease mutants with substrate analogs. |
| Q42143994 | Multiple independent origins of a protease inhibitor resistance mutation in salvage therapy patients |
| Q35091548 | New findings in cleavage sites variability across groups, subtypes and recombinants of human immunodeficiency virus type 1 |
| Q41913817 | Novel cytotoxic T-lymphocyte escape mutation by a three-amino-acid insertion in the human immunodeficiency virus type 1 p6Pol and p6Gag late domain associated with drug resistance |
| Q34010283 | Positive and negative aspects of the human immunodeficiency virus protease: development of inhibitors versus its role in AIDS pathogenesis |
| Q39580564 | Resistance-associated loss of viral fitness in human immunodeficiency virus type 1: phenotypic analysis of protease and gag coevolution in protease inhibitor-treated patients |
| Q39612306 | Retracing the evolutionary pathways of human immunodeficiency virus type 1 resistance to protease inhibitors: virus fitness in the absence and in the presence of drug |
| Q24791668 | Retroviral proteases |
| Q93140697 | Reviewing HIV-1 Gag Mutations in Protease Inhibitors Resistance: Insights for Possible Novel Gag Inhibitor Designs |
| Q90449749 | Structural Adaptation of Darunavir Analogues against Primary Mutations in HIV-1 Protease |
| Q36268829 | Structural analyses of 2015-updated drug-resistant mutations in HIV-1 protease: an implication of protease inhibitor cross-resistance |
| Q36259014 | The PTAP sequence duplication in HIV-1 subtype C Gag p6 in drug-naive subjects of India and South Africa |
| Q39689058 | The role of lysine residue at amino acid position 165 of human immunodeficiency virus type 1 CRF01_AE Gag in reducing viral drug susceptibility to protease inhibitors. |
| Q35020053 | Turnover of env variable region 1 and 2 genotypes in subjects with late-stage human immunodeficiency virus type 1 infection |
| Q37248021 | Uncoupling human immunodeficiency virus type 1 Gag and Pol reading frames: role of the transframe protein p6* in viral replication |
| Q40342948 | p6gag of human and simian immunodeficiency viruses is tolerant to small in-frame deletions downstream of the late domain |
| Q35890953 | pol gene diversity of five human immunodeficiency virus type 1 subtypes: evidence for naturally occurring mutations that contribute to drug resistance, limited recombination patterns, and common ancestry for subtypes B and D. |
Search more.